Last reviewed · How we verify
MC-1-50
At a glance
| Generic name | MC-1-50 |
|---|---|
| Sponsor | Chongqing Precision Biotech Co., Ltd |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE (PHASE1)
- Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL (PHASE1)
- Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma (PHASE1)
- Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MC-1-50 CI brief — competitive landscape report
- MC-1-50 updates RSS · CI watch RSS
- Chongqing Precision Biotech Co., Ltd portfolio CI